Skip Navigation



Japanese Journal of Clinical Oncology Advance Access published online on October 16, 2009
Japanese Journal of Clinical Oncology, doi:10.1093/jjco/hyp133
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
40/2/177    most recent
hyp133v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Ide, H.
Right arrow Articles by Oya, M.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ide, H.
Right arrow Articles by Oya, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author (2009). Published by Oxford University Press. All rights reserved

Prognostic Stratification in Patients Who Received Hormonal Therapy for Prostate-specific Antigen Recurrence after Radical Prostatectomy

Hiroki Ide, Jun Nakashima, Hidaka Kono, Eiji Kikuchi, Hirohiko Nagata, Akira Miyajima, Ken Nakagawa and Mototsugu Oya

Department of Urology, Keio University School of Medicine, Tokyo, Japan

For reprints and all correspondence: Jun Nakashima, Department of Urology, Tokyo Medical University, 6-7-1 Nishishinjiuku, Shinjiuku-Ku, Tokyo 160-0023, Japan. E-mail: njun{at}tokyo-med.ac.jp

Received July 1, 2009; accepted September 13, 2009

The present study was undertaken to investigate the predictors in patients who received hormonal therapy (HT) for prostate-specific antigen recurrence (PSAR) after surgery. Predictors for the progression-free survival were assessed in 55 patients who received HT for PSAR after surgery. In multivariate analysis, primary Gleason grade ≥4 and PSA doubling time (PSA-DT) <6 months were independent predictors. The patients were stratified into low-risk group (Gleason grade <4 and PSA-DT ≥6), high-risk group (Gleason grade ≥4 and PSA-DT <6) and intermediate-risk group (all others). In the intermediate- and high-risk groups, progression-free survival rate was significantly higher in patients with PSA level <2 than in those with PSA level ≥2 at the initiation of HT. Primary Gleason grade ≥4 and PSA-DT <6 months are independent predictors. Patients in the intermediate- and high-risk groups may benefit from early HT for PSAR after surgery.

Key Words: prostate cancer • radical prostatectomy • hormonal therapy • PSA doubling time • Gleason grade


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.